News 2014

Cristal Therapeutics announces collaboration with PX Biosolutions to develop CriVac® based vaccines

Date: 14/07/2015

14 July 2015, Maastricht – Cristal Therapeutics, a privately-held life sciences company developing innovative products against cancer and other diseases, by using its patented nanotechnology platforms, today announced the start of a collaboration with PX Biosolutions (Melbourne, Australia). The joint research and development is focussed on the application of Cristal Therapeutics’ vaccine technology CriVac® for the design of innovative vaccines.

The CriVac® platform enables the tailor-made development of well-characterized polymeric nanoparticles of a specific size, that allow optimal antigen presentation to dendritic cells. CriVac® is one of the proprietary nanotechnology platforms of Cristal Therapeutics, next to CriPec®.

PX Biosolutions is an Australian based company operating from Melbourne, Victoria. PX Biosolutions’ scientists have developed DCtagTM vaccine formulations against various types of cancer. These vaccine formulations have been tested successfully in animal models.

€6 million in new capital and new CEO for Cristal Therapeutics

Date: 15/12/2014

15 December 2014, Maastricht, The Netherlands  – Biopharmaceutical company Cristal Therapeutics has completed a new financing round of over €6 million (more…)

arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire

Date: 11/12/2014

11 December 2014, Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. today announced that its partner Shire has exercised its option to advance into preclinical development one or more product candidates (more…)

Financieele Dagblad: Medische start-up Encare uit Utrecht haalt € 5,5 mln op

Date: 17/11/2014

17 November 2014 – Het Financieele Dagblad besteedt aandacht aan de financieringsronde door onder andere Thuja in het Utrechtse bedrijf EnCare Biotech. Zie link.

Thuja Capital invests in Utrecht UMC spin-off EnCare Biotech BV

Date: 17/11/2014

17 November 2014, Utrecht – EnCare Biotech B.V., a newly founded spin-off company from University Medical Center Utrecht, has successfully closed a Series A financing round of EUR 5.5 M (more…)

arGEN-X Submits IND Application to Evaluate ARGX-110 in Waldenström’s Macroglobulinemia

Date: 03/11/2014

3 November 2014, Breda, The Netherlands / Ghent, Belgium – arGEN-X announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b/2 trial of ARGX-110 (more…)

Strategic Investment by SkylineDx in Cancer Vaccine Company DCPrime

Date: 29/10/2014

28 October 2014, Rotterdam & Leiden – SkylineDx, an innovative company in the field of genetic testing for blood cancers, announced today a strategic investment of an undisclosed sum in the Dutch cancer vaccine company DCPrime. (more…)

arGEN-X completes recruitment of first part of Phase 1 patient study

Date: 15/10/2014

15 October 2014 – Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) has completed enrolment of the first expansion cohort of 15 patients with CD70-positive hematological malignancies (more…)

Article in FD (Bijlage Biotechnologie)

Date: 29/09/2014

29 september 2014 – Financieele Dagblad – Bijlage Biotechnologie – article featuring Harrold van Barlingen

ArGEN-X lists successfully on Euronext Brussels

Date: 10/07/2014

10 July 2014 – ArGEN-X N.V., a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announces the successful completion of its Initial Public Offering (more…)

arGEN-X and The Leukemia & Lymphoma Society Partner on Treatment of Waldenström’s Macroglobulinemia

Date: 11/06/2014

10 June 2014, Breda, the Netherlands / Ghent, Belgium – arGEN-X today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study (more…)

arGEN-X enters into long-term strategic alliance with Shire Pharmaceuticals

Date: 04/06/2014

June 4, 2014. Ghent, Belgium/Breda, the Netherlands – arGEN-X today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals. (more…)

arGEN-X announces collaboration with Bayer

Date: 28/05/2014

28 May 2014, Breda, the Netherlands – arGEN-X announced today the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X’s SIMPLE Antibody™ technology for the discovery and development of therapeutic antibodies. (more…)

Thuja Capital starts new investment funds with a focus on medical product innovations

Date: 18/04/2014

18 April 2014, Utrecht – Thuja Capital today announced the successful first closing of two new investment funds: Thuja Capital Healthcare Seed Fund II (TCHSF II) and Thuja Capital Healthcare Fund II (TCHF II). (more…)

Hemics starts cost-effectiveness and efficacy HandScan study in rheumatoid arthritis

Date: 31/03/2014

31 March 2014, Eindhoven, the Netherlands – Hemics BV announces today a multi-center clinical study to evaluate the cost effectiveness and efficacy of its HandScan in tight control treatment of rheumatoid arthritis (RA). (more…)

arGEN-X starts Phase Ib expansion cohorts with ARGX-110, a novel anti-CD70 antibody, in cancer patients

Date: 13/01/2014

13 January 2014, Breda, The Netherlands / Ghent, Belgium – arGEN-X announces that it has advanced ARGX-110, a novel anti-CD70 antibody, into the safety and efficacy expansion part of its Phase Ib study. (more…)

arGEN-X receives two preclinical milestone payments under collaboration with Shire

Date: 13/01/2014

13 January 2014, Breda, the Netherlands / Ghent, Belgium – arGEN-X announces the attainment of two important success milestones in its SIMPLE Antibody™ research and product development collaboration with Shire. (more…)

Aratana Therapeutics Acquires Okapi Sciences NV

Date: 06/01/2014

6 January 2013, Kansas City, USA and Leuven, Belgium – Aratana Therapeutics, Inc. (Nasdaq: PETX) today announced, that it has acquired Okapi Sciences NV. (more…)